Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers

Evidence for decreased platelet production

Jeffrey A. Sosman, Amit K. Verma, Steven Moss, Patricia Sorokin, Michael Blend, Basil Bradlow, Nasir Chachlani, David Cutler, Ronald Sabo, Mary Nelson, Edward Bruno, David Gustin, Marlos Viana, Ronald Hoffman

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Recombinant human interleukin 10 (rhuIL-10) inhibits the production of proinflammatory cytokines and has shown promise in the treatment of inflammatory bowel disease. Clinical trials have been accompanied by a reversible decline in platelet counts. We conducted a randomized, double-blinded, placebo-controlled, parallel group trial in 12 healthy volunteers to investigate the aetiology of rhuIL-10-induced thrombocytopenia. Eight volunteers received 8 μg/kg/d of rhuIL-10 subcutaneously, while four subjects received a placebo alone for 10 d. A reversible decline in the platelet counts from a mean of 275 x 109/l to 164 x 109/l was observed in the IL-10-treated cohort (P = 0.012). A fall in the haemoglobin mean levels was also observed in the IL-10-treated cohort from 13.7 to 11.7 g/dl (P= 0.011). No significant change was observed in the bone marrow cellularity or myeloid/erythroid ratio or in the number of megakaryocytes per high-powered field (HPF). A fall was observed in the number of megakaryocyte colony-forming units (CFU-MKs) after the administration of IL-10 compared with those receiving the placebo (P = 0.068). No difference in the change in granulocyte-macrophage CFUs (CFU-GMs), mixed lineage CFUs (CFU-GEMMs) or erythroid burst-forming units (BFU-Es) was observed when comparing the IL-10- vs. placebo-treated groups (P > 0.465). Serum cytokine levels of thrombopoietin (TPO), IL-6 and granulocyte-macrophage colony stimulating factor (GM-CSF) were not decreased following IL-10 administration. In fact, both TPO and GMCSF appeared to be slightly increased in the serum. All subjects underwent Inn111-labelled platelet survival studies with liver/spleen scans to assess splenic sequestration prior to and then on day 7 of treatment. A significant reduction in splenic sequestration of platelets (P = 0.012) was observed in the IL-10-treated group, but not in the placebo-treated subjects.

Original languageEnglish (US)
Pages (from-to)104-111
Number of pages8
JournalBritish Journal of Haematology
Volume111
Issue number1
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Thrombocytopenia
Interleukin-10
Healthy Volunteers
Blood Platelets
Placebos
Thrombopoietin
Megakaryocytes
Platelet Count
Cytokines
Myeloid Progenitor Cells
Granulocyte-Macrophage Progenitor Cells
Erythroid Precursor Cells
Granulocyte-Macrophage Colony-Stimulating Factor
Serum
Inflammatory Bowel Diseases
Granulocytes
Volunteers
Interleukin-6
Hemoglobins
Stem Cells

Keywords

  • Anaemia
  • CFU-megakaryocyte
  • Interleukin 10
  • Platelets, thrombocytopenia

ASJC Scopus subject areas

  • Hematology

Cite this

Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers : Evidence for decreased platelet production. / Sosman, Jeffrey A.; Verma, Amit K.; Moss, Steven; Sorokin, Patricia; Blend, Michael; Bradlow, Basil; Chachlani, Nasir; Cutler, David; Sabo, Ronald; Nelson, Mary; Bruno, Edward; Gustin, David; Viana, Marlos; Hoffman, Ronald.

In: British Journal of Haematology, Vol. 111, No. 1, 2000, p. 104-111.

Research output: Contribution to journalArticle

Sosman, JA, Verma, AK, Moss, S, Sorokin, P, Blend, M, Bradlow, B, Chachlani, N, Cutler, D, Sabo, R, Nelson, M, Bruno, E, Gustin, D, Viana, M & Hoffman, R 2000, 'Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: Evidence for decreased platelet production', British Journal of Haematology, vol. 111, no. 1, pp. 104-111. https://doi.org/10.1046/j.1365-2141.2000.02314.x
Sosman, Jeffrey A. ; Verma, Amit K. ; Moss, Steven ; Sorokin, Patricia ; Blend, Michael ; Bradlow, Basil ; Chachlani, Nasir ; Cutler, David ; Sabo, Ronald ; Nelson, Mary ; Bruno, Edward ; Gustin, David ; Viana, Marlos ; Hoffman, Ronald. / Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers : Evidence for decreased platelet production. In: British Journal of Haematology. 2000 ; Vol. 111, No. 1. pp. 104-111.
@article{20134aded8954c5facada36cb69c13ad,
title = "Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: Evidence for decreased platelet production",
abstract = "Recombinant human interleukin 10 (rhuIL-10) inhibits the production of proinflammatory cytokines and has shown promise in the treatment of inflammatory bowel disease. Clinical trials have been accompanied by a reversible decline in platelet counts. We conducted a randomized, double-blinded, placebo-controlled, parallel group trial in 12 healthy volunteers to investigate the aetiology of rhuIL-10-induced thrombocytopenia. Eight volunteers received 8 μg/kg/d of rhuIL-10 subcutaneously, while four subjects received a placebo alone for 10 d. A reversible decline in the platelet counts from a mean of 275 x 109/l to 164 x 109/l was observed in the IL-10-treated cohort (P = 0.012). A fall in the haemoglobin mean levels was also observed in the IL-10-treated cohort from 13.7 to 11.7 g/dl (P= 0.011). No significant change was observed in the bone marrow cellularity or myeloid/erythroid ratio or in the number of megakaryocytes per high-powered field (HPF). A fall was observed in the number of megakaryocyte colony-forming units (CFU-MKs) after the administration of IL-10 compared with those receiving the placebo (P = 0.068). No difference in the change in granulocyte-macrophage CFUs (CFU-GMs), mixed lineage CFUs (CFU-GEMMs) or erythroid burst-forming units (BFU-Es) was observed when comparing the IL-10- vs. placebo-treated groups (P > 0.465). Serum cytokine levels of thrombopoietin (TPO), IL-6 and granulocyte-macrophage colony stimulating factor (GM-CSF) were not decreased following IL-10 administration. In fact, both TPO and GMCSF appeared to be slightly increased in the serum. All subjects underwent Inn111-labelled platelet survival studies with liver/spleen scans to assess splenic sequestration prior to and then on day 7 of treatment. A significant reduction in splenic sequestration of platelets (P = 0.012) was observed in the IL-10-treated group, but not in the placebo-treated subjects.",
keywords = "Anaemia, CFU-megakaryocyte, Interleukin 10, Platelets, thrombocytopenia",
author = "Sosman, {Jeffrey A.} and Verma, {Amit K.} and Steven Moss and Patricia Sorokin and Michael Blend and Basil Bradlow and Nasir Chachlani and David Cutler and Ronald Sabo and Mary Nelson and Edward Bruno and David Gustin and Marlos Viana and Ronald Hoffman",
year = "2000",
doi = "10.1046/j.1365-2141.2000.02314.x",
language = "English (US)",
volume = "111",
pages = "104--111",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers

T2 - Evidence for decreased platelet production

AU - Sosman, Jeffrey A.

AU - Verma, Amit K.

AU - Moss, Steven

AU - Sorokin, Patricia

AU - Blend, Michael

AU - Bradlow, Basil

AU - Chachlani, Nasir

AU - Cutler, David

AU - Sabo, Ronald

AU - Nelson, Mary

AU - Bruno, Edward

AU - Gustin, David

AU - Viana, Marlos

AU - Hoffman, Ronald

PY - 2000

Y1 - 2000

N2 - Recombinant human interleukin 10 (rhuIL-10) inhibits the production of proinflammatory cytokines and has shown promise in the treatment of inflammatory bowel disease. Clinical trials have been accompanied by a reversible decline in platelet counts. We conducted a randomized, double-blinded, placebo-controlled, parallel group trial in 12 healthy volunteers to investigate the aetiology of rhuIL-10-induced thrombocytopenia. Eight volunteers received 8 μg/kg/d of rhuIL-10 subcutaneously, while four subjects received a placebo alone for 10 d. A reversible decline in the platelet counts from a mean of 275 x 109/l to 164 x 109/l was observed in the IL-10-treated cohort (P = 0.012). A fall in the haemoglobin mean levels was also observed in the IL-10-treated cohort from 13.7 to 11.7 g/dl (P= 0.011). No significant change was observed in the bone marrow cellularity or myeloid/erythroid ratio or in the number of megakaryocytes per high-powered field (HPF). A fall was observed in the number of megakaryocyte colony-forming units (CFU-MKs) after the administration of IL-10 compared with those receiving the placebo (P = 0.068). No difference in the change in granulocyte-macrophage CFUs (CFU-GMs), mixed lineage CFUs (CFU-GEMMs) or erythroid burst-forming units (BFU-Es) was observed when comparing the IL-10- vs. placebo-treated groups (P > 0.465). Serum cytokine levels of thrombopoietin (TPO), IL-6 and granulocyte-macrophage colony stimulating factor (GM-CSF) were not decreased following IL-10 administration. In fact, both TPO and GMCSF appeared to be slightly increased in the serum. All subjects underwent Inn111-labelled platelet survival studies with liver/spleen scans to assess splenic sequestration prior to and then on day 7 of treatment. A significant reduction in splenic sequestration of platelets (P = 0.012) was observed in the IL-10-treated group, but not in the placebo-treated subjects.

AB - Recombinant human interleukin 10 (rhuIL-10) inhibits the production of proinflammatory cytokines and has shown promise in the treatment of inflammatory bowel disease. Clinical trials have been accompanied by a reversible decline in platelet counts. We conducted a randomized, double-blinded, placebo-controlled, parallel group trial in 12 healthy volunteers to investigate the aetiology of rhuIL-10-induced thrombocytopenia. Eight volunteers received 8 μg/kg/d of rhuIL-10 subcutaneously, while four subjects received a placebo alone for 10 d. A reversible decline in the platelet counts from a mean of 275 x 109/l to 164 x 109/l was observed in the IL-10-treated cohort (P = 0.012). A fall in the haemoglobin mean levels was also observed in the IL-10-treated cohort from 13.7 to 11.7 g/dl (P= 0.011). No significant change was observed in the bone marrow cellularity or myeloid/erythroid ratio or in the number of megakaryocytes per high-powered field (HPF). A fall was observed in the number of megakaryocyte colony-forming units (CFU-MKs) after the administration of IL-10 compared with those receiving the placebo (P = 0.068). No difference in the change in granulocyte-macrophage CFUs (CFU-GMs), mixed lineage CFUs (CFU-GEMMs) or erythroid burst-forming units (BFU-Es) was observed when comparing the IL-10- vs. placebo-treated groups (P > 0.465). Serum cytokine levels of thrombopoietin (TPO), IL-6 and granulocyte-macrophage colony stimulating factor (GM-CSF) were not decreased following IL-10 administration. In fact, both TPO and GMCSF appeared to be slightly increased in the serum. All subjects underwent Inn111-labelled platelet survival studies with liver/spleen scans to assess splenic sequestration prior to and then on day 7 of treatment. A significant reduction in splenic sequestration of platelets (P = 0.012) was observed in the IL-10-treated group, but not in the placebo-treated subjects.

KW - Anaemia

KW - CFU-megakaryocyte

KW - Interleukin 10

KW - Platelets, thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=0033759187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033759187&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2000.02314.x

DO - 10.1046/j.1365-2141.2000.02314.x

M3 - Article

VL - 111

SP - 104

EP - 111

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -